Autres langues CARsgen Therapeutics Holdings Limited

Actions

2171

KYG1996C1006

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
6,19 ^HKD	-0,80%		+13,58%	-4,77%

29/04	CARsgen Therapeutics Holdings Limited soumet des réponses aux observations de la FDA	CI
12/04	Carsgen Therapeutics fera une présentation orale d'un médicament contre le cancer à l'ASCO 2024	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CARsgen Submitted Responses to FDA Observations	30/04
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations	29/04
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	12/04
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma	04/03
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator	01/03
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel	01/03
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet	19/01
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting	19/01
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection	16/01
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3%	15/01
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration	15/01
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6%	18/12
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27%	13/12
CARsgen Therapeutics Presents Anti-Cancer Drug Data at American Conference	12/12
CARsgen Therapeutics Holdings Presents Results of Study for Myeloma Treatment	12/12
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting	12/12
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed, Refractory Multiple Myeloma or Relapsed, Refractory Primary Plasma Cell Leukemia	05/12
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma	04/12
US FDA Grants Investigational New Drug Clearance for CARsgen Therapeutics' Anti-Tumor Drug	04/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CARsgen Therapeutics Holdings Limited

Actions

2171

KYG1996C1006

Autres langues

Filtres